CSIMarket


Glaukos Corp  (GKOS)
Other Ticker:  
 


 

Glaukos Corp

GKOS's Financial Statements and Analysis



Glaukos Corp increased forth quarter of 2023 net loss per share of $-0.74 compare to net loss per share of $-0.66 recorded in the same quarter a year ago a decrease compare to $-0.63 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.74 $  82 Mill
$-0.08     $+11M     +15.55 %



Glaukos's Revenue rose by 15.55 % in forth quarter of 2023 (Dec 31 2023) year on year, to $82 million and advanced by 6.14 % sequentially.


Glaukos is

More on GKOS's Income Statement



Glaukos's in theforth quarter of 2023 recorded net loss of $-36.779 million, an increase from net loss of $-31.465 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on GKOS's Growth

Glaukos Inventories
Inventories grew by 10.95 % to $42 million from IV. Quarter a year ago, sequentially inventories rose by 5.54 %. In Dec 31 2023 company's net cash and cash equivalents decreased by $-15 million, capital expenditures grew by -8.221-48.74%, to $-4 millions compare to same quarter a year ago

More on GKOS's Cash flow Statement


Glaukos Corp does not pay out common stock dividend.

In trailing twelve-month period Glaukos Corp payed $ -1.19 cash per share, on a free-cash flow basis .

Book value fell by -2.86 % sequentially to $9.53 per share, -10.13% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.33 per share from $ 2.51.

Company repurchased 0.24 million shares or 0.48 % in Dec 31 2023.


More on GKOS's Dividends

 Market Capitalization (Millions) 4,141
 Shares Outstanding (Millions) 48
 Total Debt (Millions $) 283
 Revenue (TTM) (Millions $) 314
 Net Income (TTM) (Millions $) -135
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) -20
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 900




Glaukos Corp does not pay out common stock dividend.

In trailing twelve-month period Glaukos Corp had negative $ -1.19 cash flow per share, on a free-cash flow basis .

Book value fell by -2.86 % sequentially to $9.53 per share, -10.13% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.33 per share from $ 2.51.

Company repurchased 0.24 million shares or 0.48 % in Dec 31 2023.


More on GKOS's Balance Sheets

 Market Capitalization (Millions) 4,141
 Shares Outstanding (Millions) 48
 Total Debt (Millions $) 283
 Revenue (TTM) (Millions $) 314
 Net Income (TTM) (Millions $) -135
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) -20
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 900
   


  News about Glaukos Corp Earnings

Headline: Glaukos Corp Sees Strong Stock Performance Despite Loss per Share Increase

Glaukos Corp, a leading ophthalmic pharmaceutical and medical technology company, has seen a significant improvement in their stock performance over the past year. The stock has improved by an impressive 87.23%, bringing the share price to a 18.66% increase during the first quarter of 2024. This upward trend in stock performance is further supported by the fact that Glaukos Corp is just 5.9% short off its 52-week high.
Despite this positive stock performance, Glaukos Corp did experience a loss per share of $-0.74 in the most recent fiscal period, compared to $-0.66 a year before. Furthermore, the loss per share has increased from $-0.63 in the prior financial reporting period. However, it's important to ...

Glaukos Corp's Deficit Strikingly Larger in Q3 2023 Earnings, Raises Questions for Future



Glaukos Corporation, a renowned ophthalmic medical technology and pharmaceutical company, recently released its financial results for the third quarter of 2023. While the company experienced a widening loss per share compared to the same period last year, it witnessed remarkable revenue growth as well as notable increases in inventories and accounts receivable. These results provide valuable insights into Glaukos Corp's performance and offer some indications of how the company may fare in the future.
Losses Per Share and Improved Earnings:
During the third quarter of 2023, Glaukos Corp reported an expanded loss of $-0.63 per share, compared to $-0.58 per share in the same period the previou...

Glaukos Corp: Second Quarter of 2023 Sees Spectacular Rise in Revenue and Decrease in Losses

Glaukos Corp, a leading company in the medical equipment and supplies industry, has reported positive fi...

Glaukos Corp's Disappointing Financial Results Leave Investors Surprised and Questioning Future Investments

Glaukos Corp, a healthcare company, has recently announced a cumulative net loss of $-139 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on investment (ROI) of -14.85%. This news may come as a shock to investors, who were likely expecting better financial performance from the company.
Furthermore, Glaukos Corp's ROI falls below the average of other healthcare companies, as 111 others have had higher returns. This statistic may lead some investors to question whether they should continue to invest in Glaukos Corp or consider alternative opportunities in the healthcare sec...


Date modified: 2024-02-24T15:28:10+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com